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Abstract
Background: Procedural sedation is increasingly needed in pediatrics. Although different drugs or drugs
association are available, which is the safest and most efficient has yet to be defined, especially in syndromic
children with increased sedation-related risk factors.
Case report: we report the case of a five-year-old child affected by alpha-mannosidosis who required procedural
sedation for an MRI scan and a lumbar puncture. We administered intranasal dexmedetomidine (4 μg/kg) 45 min
before intravenous cannulation, followed by one bolus of ketamine (1 mg/kg) for each procedure. The patient
maintained spontaneous breathing and no desaturation or any complication occurred.
Conclusion: intranasal dexmedetomidine and intravenous ketamine could be a feasible option for MRI and lumbar
puncture in children with alpha-mannosidosis needing sedation.
Keywords: Dexmedetomidine, Ketamine, Procedural sedation, Alpha-mannosidosis
Introduction
Procedural sedation is an emerging cornerstone in
pediatrics aiming to control pain, decrease fear and emo-
tional response when immobility is required or during
painful procedures. The ideal sedative drug should have
a prompt onset of action, be easy to administer, with a
short elimination half time, offering efficacious pain re-
lief without side effects. Particular attention is required
when procedural sedation is needed in patients with
disabilities associated with specific genetic disease or
neurologic impairment. These patients present reduced
communicative and expressive skills which reduce pain
recognition and cooperation and they experience more
pain and distress when compared to healthy peers [1].
Therefore, they are frequently candidates for sedation,
which is a challenge due to their comorbidities, which
cause increased sedation-related risk. For example,
children affected by storage diseases usually present
higher risks due to hypotonic pharynx and soft tissue
thickness, neck stiffness, atlantooccipital instability and
cardiopathies. They are predisposed to serious anesthetic
complications, such as airway collapse with challenging
airway management and respiratory depression with
difficult ventilation and oxygenation. In addition, their
atlanto-occipital instability can lead to spinal compres-
sion and subsequent paralysis. In these fragile patients,
anesthetic drugs such as propofol and midazolam can
facilitate cardio-respiratory complications even within
standard doses, affecting respiratory drive and airway
shape. For this reason, the association of dexmedetomi-
dine and ketamine, maintaining active upper respiratory
reflexes and minimally impacting on airway shape, could
allow safer sedation.
Finally, venous access may be troublesome, scaring
and painful for these children, who often require re-
peated hospital admissions and procedures, so that a
sedation sequence based on an intranasal premedication,
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facilitating cannulation without putting the patient at
risk, may offer further advantages.
Case report
We report the case of a five-year-old child, affected by
alpha-mannosidosis requiring a brain magnetic reson-
ance (MRI) and a lumbar puncture during a planned fol-
low-up for his enzymatic substitutive treatment. He had
received a genetic diagnosis, showing mutation of the
gene MAN2B1, because of coarse facial features and
mild mental retardation. In addition, he developed psy-
chomotor and speech retardation, recurrent respiratory
infections, inguinal hernia, vertebral body listhesis and
bilateral neurosensorial deafness. No hepatic, splenic,
cardiac or bone marrow involvement were detected.
Because of the difficult airway management and a his-
tory of snoring sleep, notwithstanding a previous adeno-
tonsillectomy procedure, we decided to associate keta-
mine and dexmedetomidine for the procedural sedation.
Clear fluids were offered up to 2 hours before the pro-
cedure. 90 min before the scheduled cannulation, the
child received a topical anesthetic cream on two possible
sites and 45 min before the cannulation attempt, intra-
nasal dexmedetomidine (4 μg/kg by mean of a Mucosal
Atomizing Device) was administered. The emla cream
was removed 20 min before the cannulation attempt, in
order to avoid stimulating the child by stripping the
dressing from the skin just before venipuncture, target-
ing a good sedation level before the puncture.
This premedication allowed to perform a painless and
fearless intravenous access. A bolus of intravenous
ketamine (1 mg/Kg) was administered twice, before both
procedures, to diminish the estimated risk of about 30%
of sedation failure with dexmedetomidine alone for MRI
[2] and the expected lumbar puncture’s pain.
The patient was monitored with end-tidal carbon diox-
ide (EtCO2) nasal cannula and pulse oximetry. During the
MRI scan the patient lied down with the head slightly ro-
tated to achieve the best airways’ patency, maintaining
spontaneous breathing without desaturations or complica-
tions (SpO2 95–98%, HR 93–97 and EtCO2 40–45).
Findings of the MRI evaluation showed a very narrow
air column in the larynx and pharynx space, confirming
the high risk of an upper respiratory collapse (Fig. 1.)
The child did not require supplemental oxygen or any
intervention. Further, he underwent lumbar puncture
after administration of another bolus of ketamine at the
same dose, lying on a side, without any complication.
Both procedures lasted a total of 55 min and an hour
after, the patient awoke in a well-appearing state.
Discussion
While sedation in high-risk patients should be managed
only by experienced pediatric anesthesiologists or
Fig. 1 MRI scan showing a very narrow air column in the larynx and pharynx space along with the significant adenotonsillay hypertrophy
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intensivists, the association of dexmedetomidine and
ketamine has already been reported as a highly effica-
cious and safe option also in the setting of procedural
sedation for children without risk factors, in the general
perspective of adequately trained and skilled pediatric
sedation providers.
Alpha-mannosidosis is a rare autosomal recessive
lysosomal storage disorder with an estimated prevalence
of one in 500,000–1,000,000 live births [3]. A decreased
alpha-mannosidase activity results in impaired glycopro-
tein degradation in the lysosomes, as well as compro-
mised cellular function and apoptosis [4]. The high
prevalence of airway obstruction and restrictive pulmon-
ary disease, cardiac impairment and cervical spine issues
put these patients to a high anesthetic risk. The upper
airways can be narrowed due to the accumulation of
mannose-rich oligosaccharides causing macroglossia,
adenotonsillary hypertrophy and thickened soft tissues
in the laryngopharynx. Other typical features are de-
formities of the skull or spine, flattened nasal bridge,
short neck, high anterior larynx, mandibular abnormal-
ities or abnormal cervical vertebrae [5]. Aiming to limit
any possible effects on respiratory functions, dexmedeto-
midine and ketamine constitute a good combo.
Ketamine is a dissociative and sedative drug, frequently
used for painful procedures, because of its potent analgesic
and amnestic effect with minimal respiratory or circulatory
depression [6]. It can be administered either via intraven-
ous, intramuscular, intranasal or oral routes. Nevertheless,
the oral and intranasal ways display a low bioavailability
and, in order to achieve adequate sedation, much higher
doses are required [7]. Most common side effects are mild
hypertension and tachycardia, emesis (8–25%), hypersaliva-
tion, hallucination, psychotomimetic effect (7%) and laryn-
gospasm (0.3%) [8]. Such adverse effects can be managed
with administration of ondansetron for vomiting and posi-
tive airway pressure to overcome laryngospasm. Hypersali-
vation usually is self-limited, not requiring any medication
[9]. Ketamine, when used by pediatricians, has an impres-
sive safety record in the literature and should be consid-
ered as a standard of care in the pediatric emergency
department [10].
Dexmedetomidine is α2-adrenoreceptor agonist that
induces sedation, anxiolysis and mild analgesia, without
respiratory depression [11]. Its main side effects are
bradycardia and hypotension, usually not requiring any
medication. While the intravenous administration is
more used in pediatric intensive care, it has been dem-
onstrated that the intranasal route has a good bioavail-
ability, decreasing children’s pain and distress and
inducing sedation as an effective premedication [12, 13].
Prophylactic use of atropine should be avoided when
using dexmedetomidine, due to the high risk of blood
pressure hypertension [14].
The most frequently used premedication sedative in
children is midazolam. Midazolam has untoward side
effects such as paradoxical reactions, respiratory depres-
sion in patients with specific risk factors, amnesia and
unpleasant taste. Moreover, when it is administered via
intranasal route, many patients complain of nasal burn-
ing and gagging even after lidocaine premedication.
Dexmedetomidine is an odorless, colorless and tasteless
solution, its intranasal use is painless and could be an in-
novative approach for pediatric premedication, in par-
ticular for a successful venous cannulation [15]. As a
matter of fact, a meta-analysis of thirteen randomized
controlled trials about premedication with dexmedeto-
midine in pediatric patients revealed the superiority of
the latter on midazolam in promoting preoperative sed-
ation and decreasing postoperative pain [16]. Intranasal
dexmedetomidine, when used as the sole sedative drug
for pediatric MRI, requires a rescue treatment in 30% of
cases. When intranasal dexmedetomidine is associated
with oral midazolam (0.5 mg/kg) the success rate signifi-
cantly increases, but still at the age of 5 years, a 10% of
patients will require an additional treatment to ad-
equately perform MRI imaging [2].
As for ketamine, substantial data about safety of
non-anesthesiologist managed dexmedetomidine are
available [17, 18].
Several authors proposed dexmedetomidine and keta-
mine as a successful option to obtain a deeper and pain-
less sedation (Tab. 1). Their main advantage consists in
a deep and painless sleep, maintaining the respiratory
drive and active upper airway reflexes. Indeed, many
case reports described a successful and safe use of
dexmedetomidine and ketamine for procedural sedation,
also when analgesia and autonomous ventilation are re-
quired [26, 28]. For this reason, their administration
could be particularly safe when the maintenance of
spontaneous ventilation is a priority, such as patients
with cardiorespiratory comorbidities or high risk airway
obstruction [19]. In addition, their pharmacological
association may prevent each other’s adverse events,
having limited effects on respiratory function. Dexmede-
tomidine counteracts tachycardia, hypertension and
emergence agitation from ketamine, while the latter
prevents bradycardia and hypotension which has been
reported with dexmedetomidine [29]. The most frequent
drawbacks of the association are nausea and vomiting,
preventable with ondansetron’s administration, and a
long recovery time.
Premedication with intranasal dexmedetomidine
followed by intravenous ketamine may offer significant
advantages, facilitating venous access in patients requir-
ing painful procedures, in which the use of dexmedeto-
midine only could not guarantee an adequate level of
pain control and sedation.
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Conclusion
This is the first case described in literature in which a
child with alpha-mannosidosis successfully underwent
procedural sedation with intranasal dexmedetomidine
and intravenous ketamine.
This case highlights the advantages of the association
of intranasal dexmedetomidine followed by intravenous
ketamine. Further prospective studies should follow this
proof of concept.
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